Avadel Pharmaceuticals — FY2016 Earnings Presentation
19 slides from Avadel Pharmaceuticals's earnings presentation, Mar 7, 2017
Slide 1: Year-End 2016 Earnings Conference Call
Year-End 2016 Earnings Conference Call March 7, 2017
Slide 2: Safe Harbor
2 Safe Harbor This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estima
Slide 3: Call Outline
3 Call Outline • Share Repurchase Program • REST-ON Trial • Special Protocol Assessment • Timeline • Patent Landscape • Base Business Overview • Akovaz® • Vazculep® • Bloxiverz® • R&D Pipeline • Non-GAAP Financial Results • GAAP Financial Results • Product Sales • Cash Flow • 2017 Guidance
Slide 4: Share Repurchase Program
4 Share Repurchase Program Board of Directors authorized share repurchase program of up to $25 million Strong cash position allows flexibility to allocate money for share repurchase Provides opportunity to purchase shares and return cash to shareholders Repurchases may be made in open-market transac
Slide 5: REST-ON Phase III Trial
5 REST-ON Phase III Trial • Reached protocol agreement with FDA via Special Protocol Assessment in Q4 • Upfront agreement from FDA on powering and trial design • Endpoints: Excessive Daytime Sleepiness (EDS) and Cataplexy • Initiated patient enrollment and dosing in Q4 • Active enrollment in Europe
Slide 6: Sodium Oxybate Patent Landscape
6 Sodium Oxybate Patent Landscape 1st generic approved with separate REMS from Xyrem® Generic litigation of patent surrounding concomitant use with valproate sodium slated for May 2017 • Potential settlement prior to trial • Patent holds – generics likely delayed until 2026 • Patent falls – potentia
Slide 7: Hospital Products
7 Hospital Products • Akovaz® successfully launched in August Q3 • Exited 2016 with approximately 27% market share ( ~7.5 million vials / year) • 1 competitor in 2016 • 2 competitors in 2017 • Expect to garner and retain ~ 30% of overall market • Vazculep® had 100% share of 5mL & 10mL markets • 40%
Slide 8: Internal Development Pipeline
8 Internal Development Pipeline Indication: CNS Indication: Psychiatric Indication: Pediatric Indication: Pediatric • Numerous internal development opportunities under evaluation • Expect to file 4th NDA for AV001 by year end 2017 • Evaluating more unapproved marketed drugs (UMD) for potential devel
Slide 9: Non-GAAP Financial Results
9 Non-GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix (in 000s) 12/31/16 09/30/16 12/31/15 12/31/16 12/31/15 Sales 43,085$ 32,087$ 44,568$ 150,246$ 173,009$ Cost of products and services sold 3,610 2,844 2,937 12,742 11,410 Research and development expenses
Slide 10: GAAP Financial Results
10 GAAP Financial Results (in 000s) 12/31/16 09/30/16 12/31/15 12/31/16 12/31/15 Sales 43,085$ 32,087$ 44,568$ 150,246$ 173,009$ Cost of products and services sold 2,591 2,844 2,937 13,248 11,410 Research and development expenses 13,476 8,143 5,161 34,611 25,608 Selling, general and admin expenses 1
Slide 11: Product Sales
11 Product Sales in $000's Q1 2016 Q2 2016 Q3 2016 Q4 2016 Full Year 2016 Full Year 2015 Bloxiverz 24,747$ 25,620$ 15,591$ 16,938$ 82,896$ 150,083$ Vazculep 9,406 10,421 9,340 10,629 39,796 20,151 Akovaz - - 5,568 11,263 16,831 - Other 1,200 2,124 841 3,534 7,699 2,054 Total product sales and servic
Slide 12: Cash Flow Summary
12 Cash Flow Summary in $000's 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance 144,802$ 92,834$ Operating Cash Flows (excl tax and earnout payments) 68,801$ 126,414 Tax Payments (27,180)$ (42,121) Earnout/Royalty Payments (30,837)$ (27,897) Capital Spending (1,201)$ (1,629) Repaymen
Slide 13: Full Year 2017 Guidance - Reaffirmed
13 Full Year 2017 Guidance - Reaffirmed 2017 Guidance Sales $170M - $200M Diluted EPS (Adjusted) $0.20 - $0.35
Slide 14: Appendix
14 APPENDIX
Slide 15: GAAP to Non-GAAP Reconciliations: Three Months Ended December 31, 2016
15 GAAP to NON-GAAP Reconciliations Three Months Ended December 31, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Conting
Slide 16: GAAP to Non-GAAP Reconciliations: Three Months Ended September 30, 2016
16 GAAP to NON-GAAP Reconciliations Three Months Ended September 30, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adjustments NON-GAAP
Slide 17: GAAP to Non-GAAP Reconciliations: Three Months Ended December 31, 2015
17 GAAP to NON-GAAP Reconciliations Three Months Ended December 31, 2015: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adjustments NON-GAAP
Slide 18: GAAP to Non-GAAP Reconciliations: Twelve Months Ended December 31, 2016
18 GAAP to NON-GAAP Reconciliations Twelve Months Ended December 31, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contin
Slide 19: GAAP to Non-GAAP Reconciliations: Twelve Months Ended December 31, 2015
19 GAAP to NON-GAAP Reconciliations Twelve Months Ended December 31, 2015: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adjustments NON-GAAP
Avadel Pharmaceuticals — FY2016 Earnings Presentation on 6ix